Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356930 | 1.00 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2356933 | 1.00 | HTR2C (0.41) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL18340933 | 0.83 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2146179 | 0.83 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2502213 | 0.83 | HTR2C (0.46) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL20298070 | 0.81 | HTR2C (0.40) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL9519485 | 0.81 | SMN1; SMN2 (0.40) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL1336851 | 0.80 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2493522 | 0.80 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL17237781 | 0.80 | HTR2C (0.45) | HTR2CSMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-10227331-B2 | Metallo-β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | Marck Sharp & Dohme Corp. (US) | 2018-06-28 | — | — | US | disclosed |
| WO-2011092671-A1 | PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES | RANBAXY LABORATORIES LIMITED (IN) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227331-B2 | Metallo-β-lactamase inhibitors | ALPI, GAA, ZFX | HTR2C 4810/4885SMN1; SMN2 1991/4885NPC1 1020/4885 |
| US-20180179190-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ALPI, GAA, ZFX | HTR2C 4801/4885SMN1; SMN2 2007/4885NPC1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.